Search
for
Sort by
Research 30 of 783
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- The role of lymphocytes in the development and treatment of alopecia areata
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Immune checkpoint inhibitor‐related alopecia: Insight into the pathophysiology utilizing non‐invasive diagnostic techniques
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Cutaneous manifestations associated with immune checkpoint inhibitors
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
- Folate receptor β performs an immune checkpoint function in activated macrophages
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Hedgehog Pathway Inhibitors against Tumor Microenvironment
- CD201+ fascia progenitors choreograph injury repair
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- Editors’ Picks
- Nanomedicine-based immunotherapy for tissue regeneration
- Tregs: Where We Are and What Comes Next?
- A bibliometric analysis of T cell and atherosclerosis
- Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance
- Dermatologic Adverse Events from Cancer Treatments